ScarsPhase 2NCT06122090
Treatment of Hypopigmented Scars With Bimatoprost
A Phase 2 study testing Bimatoprost and Saline in people with Scars and Hypopigmented Scar, run by Medstar Health Research Institute at 1 site in United States.
Trial summary
Patients who have hypo-pigmented burn scar will have two scars chosen and randomized to treated scar and control scar. The subject will then have both scars treated with fractional ablative CO2 laser (FLSR). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Scars, Hypopigmented Scar, Hypopigmented Skin
- What is being tested?
- Bimatoprost and Saline
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Jul 2023to 31 Jul 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Cutaneous trauma resulting in hypopigmented scar
- 2 different hypopigmented scars (at least 30cm2 each) with at least 2 inches of normal skin, hyperpigmented scar, or hypopigmented scar separating each hypopigmented study site scar
Who cannot join
- Target hypopigmented scar to face or genitalia
- Known allergy to bimatoprost
- Known allergy to lidocaine
- Positive urine pregnancy test in women of childbearing potential (per point of care test)
- Lactating women (self-reported)
- Prisoner status
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010
Bonnie Carney, PhD, bonnie.c.carney@medstar.net
About this study
Official title: Evaluation of Laser-assisted Drug Delivery of Bimatoprost for the Treatment of Hypertrophic Scar Hypopigmentation: A Within Patient-Controlled Trial in Skin of Color
Patients who have hypo-pigmented burn scar will have two scars chosen and randomized to treated scar and control scar. The subject will then have both scars treated with fractional ablative CO2 laser (FLSR). The treated scar will have bimatoprost delivered through the laser channels, while the control will have the vehicle (normal saline) only delivered. The treatment will continue for 14 days with twice daily application. The scars will then be monitored at a 2-week follow-up visit where levels of melanin will be evaluated. Tissue punch biopsies will also be used to evaluate the mechanism of action of bimatoprost. Treatment will occur for 6 sessions at 4-6 week intervals including follow- up visits and evaluations.
Read the detailed description
If the subject agrees to take part in this study, the subject's scars will be looked at and the investigators will pick two sites that will be involved in the research. Each scar will be "randomized" into one of two study groups. One scar will be the treatment group which will be treated with standard of care therapies plus the fractionated ablative CO2 laser and topical bimatoprost drug. The other scar will be the control group which will be treated with standard of care therapies, the fractional ablative CO2 laser, and a control solution. Randomization means that either of the two scars has an equal chance of being designated as the treatment or control group. It is like flipping a coin. Neither the subject nor the investigators will choose what scar will be treated or control. Each half has a 50% chance of being placed in either group.
This study will take place in an outpatient setting. Subjects will not be admitted to the hospital overnight. Patients who enter the study will need to be able to follow up for regular appointments with the burn department.
Before the investigators start the laser treatment, the subject will come in for a pre-treatment visit where the investigators will collect information about the scars such as pictures, non-invasive probes, non-invasive imaging (ultrasound), and questionnaires filled out by the subject and the provider. These questionnaires will be related to the symptoms and appearance of scars. The questionnaires will also evaluate overall psychological health. There will also be a blood draw where less than 2 tablespoons of blood are collected. It is estimated this visit will take less than 1 hour. The investigators will also collect information from the medical record about prior surgical and medical history.
Laser treatments will occur at approximately 4-8-week intervals depending on what the Burn Center scheduling department allows. For completion of this study, the subject will undergo 6 laser treatments which should take about 6-12 months. During each laser treatment visit, the treated scar will have the drug (bimatoprost) rubbed on top of the scar while the subject is having their surgery. The subject will then continue to apply these drops to their scar for 14 days after the surgery, once in the morning and once at night. The drug will come in a bottle with a dropper top which the subject will apply a couple of drops to their scar and rub it in. The investigators will tell the subject how much drug to apply based on the size of their scar. This drug will be provided to the subject by the research pharmacy and will not be billed to the subject's insurance. The study team will call to remind the subject about their laser visits and to make sure they are applying the ointment for 14 days. The subject will apply the study drug to one scar and the control drug to the other scar. The investigators will label the containers so subjects will know which one to apply where. The subject will write down when they apply their medications in a diary entry that will be completed daily for 14 days after each laser procedures.
While most patients with burn scars undergo 6 treatments, and this is the goal for this study, sometimes depending on how the subject's scar is responding to treatment, they along with their clinical team may decide to stop treatments before the subject gets to 6 treatments, or continue after 6 treatments. Treatments of scars will stop when the clinical team elects to stop laser treatment.
If this means that the subject will only receive 1, 2, 3, 4, or 5 laser treatments instead of 6, then the subject will go into long-term follow up for the study. However, if that means the subject will get more than 6 laser treatments as a part of their clinical care, they will no longer apply the investigational drug after 6 treatments. The subject's laser surgeries will not be any longer because of their participation in the study, they will take the same amount of time as if they were not a study participant.
Treated scars will be assessed at these regular intervals: within 18 days ± 3 days following each treatment, and 12 months ± 1 month after the final study laser treatment. During the 12-month follow-up, there will also be a blood draw where less than 2 tablespoons of blood are collected. The study team will call the subject to remind them about their follow-up visits so that they can make every effort to be there. The follow-up visits will take about 30 minutes-1 hour and will be with a member of the research team. These visits can be scheduled right after the subject will be returning to see their rehab therapist for their post-laser assessment. The subject would have to come back to these follow-ups as a part of their routine clinical care any way if they were not a part of this research study.
A 3mm punch biopsy will be collected from the treatment and control scars at each laser treatment visit (Laser surgery #1, #2, #3, #4, #5, and #6). Two 3mm punch biopsies will be taken of non-burned skin only at the first laser treatment. These biopsies will be taken when the subject is under anesthesia as a part of their laser surgery.
At study entrance and at each study visit, photographs will be taken of the control and treated scars. All photographs taken for the purpose of this study will be taken by a study camera, with images stored on a password-protected secure server. These photographs will be labeled with a study ID number. All efforts will be made to minimize the amount of identifiable information such as the face or tattoos in these photos.
- Conditions
- Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic
- Being tested
- Bimatoprost, Saline
- Keywords
- burn hypertrophic scar, burn scar hypopigmentation, scar, hypopigmentation, dyschromia, pigmentation abnormality
- Medical subject headings
- Cicatrix, Vitiligo, Cicatrix, Hypertrophic, Pigmentation Disorders, Hypopigmentation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BimatoprostDrug
Bimatoprost will be delivered with laser
SalineDrug
Saline control will be delivered with laser
| Study group | Role | What they receive |
|---|---|---|
| Treatment | Experimental | Bimatoprost will be delivered to the scars using laser-assisted drug delivery in this arm Receives: Drug: Bimatoprost |
| Control | Sham comparator | Saline control will be delivered to the scars using laser-assisted drug delivery in this arm Receives: Drug: Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area of pigmentation
area of pigmentation within control and treated scars
Measured: follow-up number 6, an average of 8 months
Secondary outcomes (4)
Melanin Index
Melanin index of hypopigmented burn scars (minimum=500, maximum=950, higher score correlates with a better outcome)
Measured: follow-up number 6, an average of 8 months
Differential gene expression of tyrosinase
pigmentation signaling molecules within tissue punch biopsies
Measured: follow-up number 6, an average of 8 months
Differential gene expression of tyrosinase-related protein 1
pigmentation signaling molecules within tissue punch biopsies
Measured: follow-up number 6, an average of 8 months
Differential gene expression of tyrosinase-related protein 2
pigmentation signaling molecules within tissue punch biopsies
Measured: follow-up number 6, an average of 8 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2023
- Study start18 Jul 2023
- Primary completion30 Dec 2024 (estimated)
- Study completion31 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ScarsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medstar Health Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Latham Fund
- Responsible party
- Principal investigator, Bonnie Carney, Medstar Health Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06122090
- Sponsor's protocol ID
- 00006189
- Status last verified
- May 2024
- First submitted
- 11 Aug 2023
- Last updated
- 3 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Laser-assisted Drug Delivery of Bimatoprost for the Treatment of Hypertrophic Scar Hypopigmentation: A Within Patient-Controlled Trial in Skin of Color
- ClinicalTrials.gov ID
- NCT06122090
- Acronym / sponsor ID
- 00006189
- Conditions
- Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic
- Keywords
- burn hypertrophic scar, burn scar hypopigmentation, scar, hypopigmentation, dyschromia, pigmentation abnormality
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Medstar Health Research InstituteUniversity, hospital or other
- Collaborators
- Latham Fund
- Study start
- 18 Jul 2023 (actual)
- Primary completion
- 30 Dec 2024 (estimated)
- Study completion
- 31 Jul 2025 (estimated)
- First posted
- 8 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients who have hypo-pigmented burn scar will have two scars chosen and randomized to treated scar and control scar. The subject will then have both scars treated with fractional ablative CO2 laser (FLSR). The treated scar will have bimatoprost delivered through the laser channels, while the control will have the vehicle (normal saline) only delivered. The treatment will continue for 14 days with twice daily application. The scars will then be monitored at a 2-week follow-up visit where levels of melanin will be evaluated. Tissue punch biopsies will also be used to evaluate the mechanism of action of bimatoprost. Treatment will occur for 6 sessions at 4-6 week intervals including follow- up visits and evaluations.
Detailed description
If the subject agrees to take part in this study, the subject's scars will be looked at and the investigators will pick two sites that will be involved in the research. Each scar will be "randomized" into one of two study groups. One scar will be the treatment group which will be treated with standard of care therapies plus the fractionated ablative CO2 laser and topical bimatoprost drug. The other scar will be the control group which will be treated with standard of care therapies, the fractional ablative CO2 laser, and a control solution. Randomization means that either of the two scars has an equal chance of being designated as the treatment or control group. It is like flipping a coin. Neither the subject nor the investigators will choose what scar will be treated or control. Each half has a 50% chance of being placed in either group.
This study will take place in an outpatient setting. Subjects will not be admitted to the hospital overnight. Patients who enter the study will need to be able to follow up for regular appointments with the burn department.
Before the investigators start the laser treatment, the subject will come in for a pre-treatment visit where the investigators will collect information about the scars such as pictures, non-invasive probes, non-invasive imaging (ultrasound), and questionnaires filled out by the subject and the provider. These questionnaires will be related to the symptoms and appearance of scars. The questionnaires will also evaluate overall psychological health. There will also be a blood draw where less than 2 tablespoons of blood are collected. It is estimated this visit will take less than 1 hour. The investigators will also collect information from the medical record about prior surgical and medical history.
Laser treatments will occur at approximately 4-8-week intervals depending on what the Burn Center scheduling department allows. For completion of this study, the subject will undergo 6 laser treatments which should take about 6-12 months. During each laser treatment visit, the treated scar will have the drug (bimatoprost) rubbed on top of the scar while the subject is having their surgery. The subject will then continue to apply these drops to their scar for 14 days after the surgery, once in the morning and once at night. The drug will come in a bottle with a dropper top which the subject will apply a couple of drops to their scar and rub it in. The investigators will tell the subject how much drug to apply based on the size of their scar. This drug will be provided to the subject by the research pharmacy and will not be billed to the subject's insurance. The study team will call to remind the subject about their laser visits and to make sure they are applying the ointment for 14 days. The subject will apply the study drug to one scar and the control drug to the other scar. The investigators will label the containers so subjects will know which one to apply where. The subject will write down when they apply their medications in a diary entry that will be completed daily for 14 days after each laser procedures.
While most patients with burn scars undergo 6 treatments, and this is the goal for this study, sometimes depending on how the subject's scar is responding to treatment, they along with their clinical team may decide to stop treatments before the subject gets to 6 treatments, or continue after 6 treatments. Treatments of scars will stop when the clinical team elects to stop laser treatment.
If this means that the subject will only receive 1, 2, 3, 4, or 5 laser treatments instead of 6, then the subject will go into long-term follow up for the study. However, if that means the subject will get more than 6 laser treatments as a part of their clinical care, they will no longer apply the investigational drug after 6 treatments. The subject's laser surgeries will not be any longer because of their participation in the study, they will take the same amount of time as if they were not a study participant.
Treated scars will be assessed at these regular intervals: within 18 days ± 3 days following each treatment, and 12 months ± 1 month after the final study laser treatment. During the 12-month follow-up, there will also be a blood draw where less than 2 tablespoons of blood are collected. The study team will call the subject to remind them about their follow-up visits so that they can make every effort to be there. The follow-up visits will take about 30 minutes-1 hour and will be with a member of the research team. These visits can be scheduled right after the subject will be returning to see their rehab therapist for their post-laser assessment. The subject would have to come back to these follow-ups as a part of their routine clinical care any way if they were not a part of this research study.
A 3mm punch biopsy will be collected from the treatment and control scars at each laser treatment visit (Laser surgery #1, #2, #3, #4, #5, and #6). Two 3mm punch biopsies will be taken of non-burned skin only at the first laser treatment. These biopsies will be taken when the subject is under anesthesia as a part of their laser surgery.
At study entrance and at each study visit, photographs will be taken of the control and treated scars. All photographs taken for the purpose of this study will be taken by a study camera, with images stored on a password-protected secure server. These photographs will be labeled with a study ID number. All efforts will be made to minimize the amount of identifiable information such as the face or tattoos in these photos.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment | Experimental | Drug: BimatoprostBimatoprost will be delivered to the scars using laser-assisted drug delivery in this arm |
| Control | Sham comparator | Drug: SalineSaline control will be delivered to the scars using laser-assisted drug delivery in this arm |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥ 18 years
- Cutaneous trauma resulting in hypopigmented scar
- 2 different hypopigmented scars (at least 30cm2 each) with at least 2 inches of normal skin, hyperpigmented scar, or hypopigmented scar separating each hypopigmented study site scar
Key exclusion criteria (6 listed)
- Target hypopigmented scar to face or genitalia
- Known allergy to bimatoprost
- Known allergy to lidocaine
- Positive urine pregnancy test in women of childbearing potential (per point of care test)
- Lactating women (self-reported)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BimatoprostBimatoprost will be delivered with laser | Drug | Treatment |
| SalineSaline control will be delivered with laser | Drug | Control |
Primary outcome
Area of pigmentation
Time frame: follow-up number 6, an average of 8 months
area of pigmentation within control and treated scars
4 secondary outcomes
Melanin Index
Time frame: follow-up number 6, an average of 8 months
Differential gene expression of tyrosinase
Time frame: follow-up number 6, an average of 8 months
Differential gene expression of tyrosinase-related protein 1
Time frame: follow-up number 6, an average of 8 months
Differential gene expression of tyrosinase-related protein 2
Time frame: follow-up number 6, an average of 8 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2024.
Related trials for Scars
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
Ventricular Tachycardia
Not yet recruitingPhase 2
Phase II Clinical Study on Preliminary Efficacy and Safety of ETD-001 Gel for Hypertrophic Scars
Hypertrophic Scars
Not yet recruitingObservational study
CIC101-02-LT is a Long-term Follow-up Study of Subjects Treated With TRTP-101 and Will Evaluate the Long-term Safety and Efficacy of TRTP-101.
Atrophic Scar
Not yet recruiting
Autologous Skin Cell Suspension (RECELL®) for Accelerated Healing of Split-Thickness Skin Graft Donor Sites: A Randomized, Intra-Patient (Split-Site) Controlled Trial
Skin Graft Donor Site, Wound Healing
Not yet recruitingObservational study
Recurrence of Extremity Joint Contracture After Z-Plasty Versus Full-Thickness Skin Graft
Joint Contracture, Contracture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Bimatoprost and Saline in people with Scars and Hypopigmented Scar, run by Medstar Health Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Alison Ross, BA (202-877-5170, fbsrlresearch@medstar.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area of pigmentation (time frame: follow-up number 6, an average of 8 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2024.